EMA starts review of Skycovion COVID-19 vaccine application

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a review of a conditional marketing authorization application for Skycovion, a vaccine for protecting against COVID-19.

The applicant, Germany-based SK Chemicals GmbH, has submitted data on how well the vaccine triggers the production of antibodies against the original strain of SARS-CoV-2, the virus that causes COVID-19. The company also submitted data on the safety and quality of the vaccine.

After reviewing the data, the CHMP will issue an opinion on whether to grant a conditional marketing authorization. The European Commission will then make a legally binding decision. The EMA will communicate further at the time of CHMP’s opinion.